Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse

References

• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73. doi:10.1186/s12916-016-0623-5.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20, 651–668.doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–12. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020. doi:10.1038/s41422-020-0343-4.
   Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662. doi:10.1038/nrd4663.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–567. doi:10.1038/nrc3770.
   PubMed Web of Science ®Google Scholar
• Ledford H. Cancer-fighting viruses win approval. Nature. 2015;526(7575):622–623. doi:10.1038/526622a.
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475.
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219–233. doi:10.1038/nrc.2016.16.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. doi:10.1038/s41541-019-0103-y.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520–3526. doi:10.1158/1078-0432.CCR-10-3126.
   PubMed Web of Science ®Google Scholar
• Martinez-Saez N, Peregrina JM, Corzana F. Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides. Chem Soc Rev. 2017;46(23):7154–7175. doi:10.1039/C6CS00858E.
   PubMed Web of Science ®Google Scholar
• Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332–342. doi:10.1016/j.molmed.2014.02.007.
   PubMed Web of Science ®Google Scholar
• Beckwith DM, Cudic M. Tumor-associated O-glycans of MUC1: carriers of the glyco-code and targets for cancer vaccine design. Semin Immunol. 2020;47:101389. doi:10.1016/j.smim.2020.101389.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61–70. doi:10.1038/nrc2293.
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61(16):5964–5968.
   PubMed Web of Science ®Google Scholar
• Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000;60(7):1815–1817.
   PubMed Web of Science ®Google Scholar
• Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016;16:49. doi:10.1186/s12935-016-0326-1.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang H-B, Cai L, Janofsky S, Chew A, Storek J, Akpek G, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117(3):788–797. doi:10.1182/blood-2010-08-299396.
   PubMed Web of Science ®Google Scholar
• Gaidzik N, Westerlind U, Kunz H. The development of synthetic antitumour vaccines from mucin glycopeptide antigens. Chem Soc Rev. 2013;42(10):4421–4442. doi:10.1039/c3cs35470a.
   PubMed Web of Science ®Google Scholar
• Acres B, Lacoste G, Limacher JM. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. Curr Top Microbiol Immunol. 2017;405:79–97.
   PubMed Web of Science ®Google Scholar
• Disis ML, Gad E, Herendeen DR, Lai V-P, Park KH, Cecil DL, O’Meara MM, Treuting PM, Lubet RA. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila). 2013;6(12):1273–1282. doi:10.1158/1940-6207.CAPR-13-0182.
   PubMed Web of Science ®Google Scholar
• Chen J, Guo X-Z, Li H-Y, Liu X, Ren L-N, Wang D, Zhao -J-J. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. Vaccine. 2013;31(41):4585–4590. doi:10.1016/j.vaccine.2013.07.055.
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marté JL, Cordes LM, Lamping E, et al. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clin Cancer Res. 2019;25(16):4933–4944. doi:10.1158/1078-0432.CCR-19-0183.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu C, Zhang F, Geng F, Xia Q, Lu Z, Xu P, Xie Y, Wu H, Yu B, et al. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016;34(24):2648–2655. doi:10.1016/j.vaccine.2016.04.045.
   PubMed Web of Science ®Google Scholar
• Liu C, Lu Z, Xie Y, Guo Q, Geng F, Sun B, Wu H, Yu B, Wu J, Zhang H, et al. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunol Lett. 2018;200:33–42. doi:10.1016/j.imlet.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108–120. doi:10.1038/nrc2326.
   PubMed Web of Science ®Google Scholar
• Grunwald T, Tenbusch M, Schulte R, Raue K, Wolf H, Hannaman D, de Swart RL, Uberla K, Stahl-Hennig C. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. J Virol. 2014;88(8):3997–4007. doi:10.1128/JVI.02736-13.
   PubMed Web of Science ®Google Scholar
• Gary EN, Weiner DB. DNA vaccines: prime time is now. Curr Opin Immunol. 2020;65:21–27. doi:10.1016/j.coi.2020.01.006.
   PubMed Web of Science ®Google Scholar
• Lim M, Badruddoza AZM, Firdous J, Azad M, Mannan A, Al-Hilal TA, Cho C-S, Islam MA. Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies. Pharmaceutics. 2020;12(1). doi:10.3390/pharmaceutics12010030.
   Web of Science ®Google Scholar
• Gomez-Aguado I, Rodriguez-Castejon J, Vicente-Pascual M, Rodriguez-Gascon A, Solinis MA, Del Pozo-Rodriguez A. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials (Basel). 2020;10(2):364.doi:10.3390/nano10020364.
   Google Scholar
• DeMuth PC, Min Y, Huang B, Kramer JA, Miller AD, Barouch DH, Hammond PT, Irvine DJ. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013;12(4):367–376. doi:10.1038/nmat3550.
   PubMed Web of Science ®Google Scholar
• Reparaz D, Llopiz D, Sarobe P. When Cancer Vaccines Go Viral. Clin Cancer Res. 2019;25(16):4871–4873. doi:10.1158/1078-0432.CCR-19-1652.
   PubMed Web of Science ®Google Scholar
• Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine. 2013;31(39):4247–4251. doi:10.1016/j.vaccine.2013.03.021.
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346–351. doi:10.1016/j.coi.2009.05.016.
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WHH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003;9(6):729–735. doi:10.1038/nm881.
   PubMed Web of Science ®Google Scholar
• Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, et al. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses. 2010;2(2):435–467. doi:10.3390/v2020435.
   PubMed Web of Science ®Google Scholar
• Hallengard D, Lum F-M, Kummerer BM, Lulla A, Lulla V, Garcia-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, et al. Prime-boost immunization strategies against Chikungunya virus. J Virol. 2014;88(22):13333–13343. doi:10.1128/JVI.01926-14.
   PubMed Web of Science ®Google Scholar
• Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer. 2005;113(2):259–266. doi:10.1002/ijc.20569.
   PubMed Web of Science ®Google Scholar
• Kim SB, Ahn J-H, Kim J, Jung KH. A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. Mol Ther Methods Clin Dev. 2015;2:15031. doi:10.1038/mtm.2015.31.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother. 2012;61(10):1857–1867. doi:10.1007/s00262-012-1296-3.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Zhang -H-H, Liu C-L, Wu H, Wang P, Xia Q, Zhang L-X, Li B, Wu J-X, Yu B, et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol. 2013;17(1):9–17. doi:10.1016/j.intimp.2013.04.015.
   PubMed Web of Science ®Google Scholar
• Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol. 2004;172(10):6265–6271. doi:10.4049/jimmunol.172.10.6265.
   PubMed Web of Science ®Google Scholar
• Park A, Fong Y, Kim S, Yang J, Murad J, Lu J et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020;12(559)eaaz1863. doi:10.1126/scitranslmed.aaz1863.
   Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221. doi:10.1038/nature22991.
   PubMed Web of Science ®Google Scholar
• Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814–824. doi:10.1038/s41591-019-0410-x.
   PubMed Web of Science ®Google Scholar
• Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8–16. doi:10.1016/j.ctrv.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Geng F, Bao X, Dong L, Guo -Q-Q, Guo J, Xie Y, Zhou Y, Yu B, Wu H, Wu J-X, et al. Doxorubicin pretreatment enhances FAPalpha/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model. Oncoimmunology. 2020;9(1):1747350. doi:10.1080/2162402X.2020.1747350.
   PubMed Web of Science ®Google Scholar
• Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809–1814. doi:10.1073/pnas.1417636112.
   PubMed Web of Science ®Google Scholar
• Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P, et al. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer. 2017;5:4. doi:10.1186/s40425-016-0204-3.
   PubMed Web of Science ®Google Scholar
• Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–1332. doi:10.1001/jamaoncol.2015.2756.
   PubMed Web of Science ®Google Scholar